Title: Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and
its potential association with immune cells
Version: 0 Date: 05 Oct 2021
Reviewer's report:
Thank you for giving me the opportunity to review your interesting manuscript titled, "
Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and its
potential association with immune cells”
I have some questions and comments.
# I cannot understand the mechanism of the relationship between upregulation of PSPH and
poor survival of gastric cancer patients. Please explain the mechanism in gastric cancer. Is this
only due to low infiltration of immune cells in gastric cancer tissue?
# Please explain the reason precisely for the relationship between high expression of PSPH of
gastric cancer cell and low infiltration of immune cells in gastric cancer tissue.
#  Please explain about the relationship between expression of PSPH and the difference of the
subtype of immune cells infiltrated in gastric cancer.
# Although it is well known that the prognosis of diffuse type gastric cancer is worse than
intestinal type because of distant metastasis especially peritoneal metastasis is common in
diffuse type, almost 65% of diffuse type gastric cancer shows low expression of PSPH,
which showed better prognosis than high PSPH expression group. Please explain about this
contradiction.
# Although in Result the author described that “High PSPH level indicates poor prognosis in
gastric cancer”, PSPH expression was not identified as prognostic factor in multivariate Cox
analysis. I think that the author should not describe as “High PSPH level indicates poor prognosis
in gastric cancer”
Minor Point
# In Method PSPH expression score was divided as negative and positive, while in Result and
Table2 PSPH expression was described as low and high.
Please unify the expression.
Title: Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and
its potential association with immune cells
Version: 0 Date: 05 Oct 2021
Reviewer's report:
Thank you for giving me the opportunity to review your interesting manuscript titled, "
Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and its
potential association with immune cells”
I have some questions and comments.
# I cannot understand the mechanism of the relationship between upregulation of PSPH and
poor survival of gastric cancer patients. Please explain the mechanism in gastric cancer. Is this
only due to low infiltration of immune cells in gastric cancer tissue?
# Please explain the reason precisely for the relationship between high expression of PSPH of
gastric cancer cell and low infiltration of immune cells in gastric cancer tissue.
#  Please explain about the relationship between expression of PSPH and the difference of the
subtype of immune cells infiltrated in gastric cancer.
# Although it is well known that the prognosis of diffuse type gastric cancer is worse than
intestinal type because of distant metastasis especially peritoneal metastasis is common in
diffuse type, almost 65% of diffuse type gastric cancer shows low expression of PSPH,
which showed better prognosis than high PSPH expression group. Please explain about this
contradiction.
# Although in Result the author described that “High PSPH level indicates poor prognosis in
gastric cancer”, PSPH expression was not identified as prognostic factor in multivariate Cox
analysis. I think that the author should not describe as “High PSPH level indicates poor prognosis
in gastric cancer”
Minor Point
# In Method PSPH expression score was divided as negative and positive, while in Result and
Table2 PSPH expression was described as low and high.
Please unify the expression.
Please review this paper.
user
Title: Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and
its potential association with immune cells
Version: 0 Date: 05 Oct 2021
Reviewer's report:
Thank you for giving me the opportunity to review your interesting manuscript titled, "
Phosphoserine Phosphatase as a prognostic biomarker in patients with gastric cancer and its
potential association with immune cells”
I have some questions and comments.
# I cannot understand the mechanism of the relationship between upregulation of PSPH and
poor survival of gastric cancer patients. Please explain the mechanism in gastric cancer. Is this
only due to low infiltration of immune cells in gastric cancer tissue?
# Please explain the reason precisely for the relationship between high expression of PSPH of
gastric cancer cell and low infiltration of immune cells in gastric cancer tissue.
#  Please explain about the relationship between expression of PSPH and the difference of the
subtype of immune cells infiltrated in gastric cancer.
# Although it is well known that the prognosis of diffuse type gastric cancer is worse than
intestinal type because of distant metastasis especially peritoneal metastasis is common in
diffuse type, almost 65% of diffuse type gastric cancer shows low expression of PSPH,
which showed better prognosis than high PSPH expression group. Please explain about this
contradiction.
# Although in Result the author described that “High PSPH level indicates poor prognosis in
gastric cancer”, PSPH expression was not identified as prognostic factor in multivariate Cox
analysis. I think that the author should not describe as “High PSPH level indicates poor prognosis
in gastric cancer”
Minor Point
# In Method PSPH expression score was divided as negative and positive, while in Result and
Table2 PSPH expression was described as low and high.
Please unify the expression.
assistant